KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Average (2016 - 2025)

Historic Equity Average for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $18.2 billion.

  • Biogen's Equity Average rose 1024.77% to $18.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.2 billion, marking a year-over-year increase of 1024.77%. This contributed to the annual value of $17.5 billion for FY2025, which is 1097.05% up from last year.
  • Per Biogen's latest filing, its Equity Average stood at $18.2 billion for Q4 2025, which was up 1024.77% from $17.9 billion recorded in Q3 2025.
  • Biogen's 5-year Equity Average high stood at $18.2 billion for Q4 2025, and its period low was $10.7 billion during Q1 2021.
  • Its 5-year average for Equity Average is $14.1 billion, with a median of $14.3 billion in 2023.
  • As far as peak fluctuations go, Biogen's Equity Average tumbled by 1749.38% in 2021, and later soared by 2251.99% in 2023.
  • Biogen's Equity Average (Quarter) stood at $10.9 billion in 2021, then grew by 19.75% to $13.1 billion in 2022, then rose by 11.94% to $14.6 billion in 2023, then grew by 12.96% to $16.5 billion in 2024, then increased by 10.25% to $18.2 billion in 2025.
  • Its Equity Average was $18.2 billion in Q4 2025, compared to $17.9 billion in Q3 2025 and $17.3 billion in Q2 2025.